Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial

Gabriele Martelli, Patrizia Boracchi, Ilaria Ardoino, Laura Lozza, Silvia Bohm, Gaetano Vetrella, Roberto Agresti

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

OBJECTIVE: To assess the role of axillary dissection in older breast cancer patients with a clinically clear axilla. BACKGROUND: Axillary dissection, once standard treatment for breast cancer, is associated with considerable morbidity. It has been substituted by sentinel node biopsy with dissection only if the sentinel node is positive. We aimed to determine whether axillary surgery can be omitted in older women, thereby sparing them morbidity, without compromising long-term disease control. METHODS: We carried out a randomized clinical trial on 238 older (65-80 years) breast cancer patients, with clinically N0 disease of radiographic diameter 2 cm or less. Patients were randomized to quadrantectomy with or without axillary dissection. All received radiotherapy to the residual breast but not the axilla; all were prescribed tamoxifen for 5 years. Main outcome measures were overall survival and breast cancer mortality. We also assessed overt axillary disease in those who did not receive axillary dissection. RESULTS: After 15 years of follow-up, distant metastasis rate, overall survival, and breast cancer mortality in the axillary dissection and no axillary dissection arms were indistinguishable. The 15-year cumulative incidence of overt axillary disease in the no axillary dissection arm was only 6%. CONCLUSIONS: Older patients with early breast cancer and a clinically clear axilla treated by conservative surgery, postoperative radiotherapy, and adjuvant tamoxifen do not benefit from axillary dissection. This study was registered at clinicaltrials.gov (ID NCT00002720).

Original languageEnglish
Pages (from-to)920-924
Number of pages5
JournalAnnals of Surgery
Volume256
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Dissection
Randomized Controlled Trials
Breast Neoplasms
Axilla
Tamoxifen
Arm
Morbidity
Adjuvant Radiotherapy
Mortality
Breast
Radiotherapy
Survival Rate
Outcome Assessment (Health Care)
Neoplasm Metastasis
Biopsy
Survival
Incidence

Keywords

  • axillary surgery
  • breast cancer
  • older patients
  • randomized trial
  • tamoxifen

ASJC Scopus subject areas

  • Surgery

Cite this

Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer : 15-year results of a randomized controlled trial. / Martelli, Gabriele; Boracchi, Patrizia; Ardoino, Ilaria; Lozza, Laura; Bohm, Silvia; Vetrella, Gaetano; Agresti, Roberto.

In: Annals of Surgery, Vol. 256, No. 6, 12.2012, p. 920-924.

Research output: Contribution to journalArticle

@article{11a7603b938c4e87aec2a9789f50b8fe,
title = "Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial",
abstract = "OBJECTIVE: To assess the role of axillary dissection in older breast cancer patients with a clinically clear axilla. BACKGROUND: Axillary dissection, once standard treatment for breast cancer, is associated with considerable morbidity. It has been substituted by sentinel node biopsy with dissection only if the sentinel node is positive. We aimed to determine whether axillary surgery can be omitted in older women, thereby sparing them morbidity, without compromising long-term disease control. METHODS: We carried out a randomized clinical trial on 238 older (65-80 years) breast cancer patients, with clinically N0 disease of radiographic diameter 2 cm or less. Patients were randomized to quadrantectomy with or without axillary dissection. All received radiotherapy to the residual breast but not the axilla; all were prescribed tamoxifen for 5 years. Main outcome measures were overall survival and breast cancer mortality. We also assessed overt axillary disease in those who did not receive axillary dissection. RESULTS: After 15 years of follow-up, distant metastasis rate, overall survival, and breast cancer mortality in the axillary dissection and no axillary dissection arms were indistinguishable. The 15-year cumulative incidence of overt axillary disease in the no axillary dissection arm was only 6{\%}. CONCLUSIONS: Older patients with early breast cancer and a clinically clear axilla treated by conservative surgery, postoperative radiotherapy, and adjuvant tamoxifen do not benefit from axillary dissection. This study was registered at clinicaltrials.gov (ID NCT00002720).",
keywords = "axillary surgery, breast cancer, older patients, randomized trial, tamoxifen",
author = "Gabriele Martelli and Patrizia Boracchi and Ilaria Ardoino and Laura Lozza and Silvia Bohm and Gaetano Vetrella and Roberto Agresti",
year = "2012",
month = "12",
doi = "10.1097/SLA.0b013e31827660a8",
language = "English",
volume = "256",
pages = "920--924",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer

T2 - 15-year results of a randomized controlled trial

AU - Martelli, Gabriele

AU - Boracchi, Patrizia

AU - Ardoino, Ilaria

AU - Lozza, Laura

AU - Bohm, Silvia

AU - Vetrella, Gaetano

AU - Agresti, Roberto

PY - 2012/12

Y1 - 2012/12

N2 - OBJECTIVE: To assess the role of axillary dissection in older breast cancer patients with a clinically clear axilla. BACKGROUND: Axillary dissection, once standard treatment for breast cancer, is associated with considerable morbidity. It has been substituted by sentinel node biopsy with dissection only if the sentinel node is positive. We aimed to determine whether axillary surgery can be omitted in older women, thereby sparing them morbidity, without compromising long-term disease control. METHODS: We carried out a randomized clinical trial on 238 older (65-80 years) breast cancer patients, with clinically N0 disease of radiographic diameter 2 cm or less. Patients were randomized to quadrantectomy with or without axillary dissection. All received radiotherapy to the residual breast but not the axilla; all were prescribed tamoxifen for 5 years. Main outcome measures were overall survival and breast cancer mortality. We also assessed overt axillary disease in those who did not receive axillary dissection. RESULTS: After 15 years of follow-up, distant metastasis rate, overall survival, and breast cancer mortality in the axillary dissection and no axillary dissection arms were indistinguishable. The 15-year cumulative incidence of overt axillary disease in the no axillary dissection arm was only 6%. CONCLUSIONS: Older patients with early breast cancer and a clinically clear axilla treated by conservative surgery, postoperative radiotherapy, and adjuvant tamoxifen do not benefit from axillary dissection. This study was registered at clinicaltrials.gov (ID NCT00002720).

AB - OBJECTIVE: To assess the role of axillary dissection in older breast cancer patients with a clinically clear axilla. BACKGROUND: Axillary dissection, once standard treatment for breast cancer, is associated with considerable morbidity. It has been substituted by sentinel node biopsy with dissection only if the sentinel node is positive. We aimed to determine whether axillary surgery can be omitted in older women, thereby sparing them morbidity, without compromising long-term disease control. METHODS: We carried out a randomized clinical trial on 238 older (65-80 years) breast cancer patients, with clinically N0 disease of radiographic diameter 2 cm or less. Patients were randomized to quadrantectomy with or without axillary dissection. All received radiotherapy to the residual breast but not the axilla; all were prescribed tamoxifen for 5 years. Main outcome measures were overall survival and breast cancer mortality. We also assessed overt axillary disease in those who did not receive axillary dissection. RESULTS: After 15 years of follow-up, distant metastasis rate, overall survival, and breast cancer mortality in the axillary dissection and no axillary dissection arms were indistinguishable. The 15-year cumulative incidence of overt axillary disease in the no axillary dissection arm was only 6%. CONCLUSIONS: Older patients with early breast cancer and a clinically clear axilla treated by conservative surgery, postoperative radiotherapy, and adjuvant tamoxifen do not benefit from axillary dissection. This study was registered at clinicaltrials.gov (ID NCT00002720).

KW - axillary surgery

KW - breast cancer

KW - older patients

KW - randomized trial

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84870008889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870008889&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e31827660a8

DO - 10.1097/SLA.0b013e31827660a8

M3 - Article

C2 - 23154393

AN - SCOPUS:84870008889

VL - 256

SP - 920

EP - 924

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -